Factory Anti-Cancer 99% Pirfenidone Powder CAS 53179-13-8 Pirfenidone

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A65
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Name: Pirfenidone
• Appearance: White Powder
• Assay: 99%
• CAS: 53179-13-8
• OEM: Available
• Sample: Available
• Suitable: Adult
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Pirfenidone
CAS	53179-13-8
Appearance	White powder
MF	C12H11NO
MW	185.22184
Purity	99%

 

Pirfenidone (PFD) is a new pyridone compound with broad-spectrum anti-fibrotic effect, which can prevent and reverse the formation of fibrosis and scarring; it was launched by Shionogi, Japan in 2008 and has been obtained. Approved by the U.S. Food and Drug Administration, it is the first drug that has demonstrated a certain efficacy in idiopathic pulmonary fibrosis (IPF) through repeated, randomized, placebo-controlled phase III clinical trials; Fibrosis, liver fibrosis and other fibrotic diseases also have good curative effect; at the same time, kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I multiple neurofibroma, adolescent I It is widely used in phase II clinical studies of multiple neurofibromas and plexiform neurofibromas, diabetes with kidney disease, and uterine leiomyoma.

 

1. Idiopathic Pulmonary Fibrosis (IPF) Treatment: Pirfenidone is primarily used for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of lung tissue.
2. Slowing Disease Progression: It is prescribed to slow down the progression of IPF, aiming to improve lung function and reduce the risk of disease-related complications.
3. Symptom Management: Alongside slowing disease progression, pirfenidone may also help manage symptoms associated with IPF, such as shortness of breath and coughing.

1. Modulation of Inflammatory and Fibrotic Pathways: Pirfenidone functions by modulating multiple inflammatory and fibrotic pathways involved in the development and progression of IPF.
2. Inhibition of Fibroblast Proliferation and Collagen Production: It inhibits the proliferation of fibroblasts, the cells responsible for producing collagen, and reduces the excessive production of collagen that leads to scarring in the lungs.
3. Antioxidant and Anti-inflammatory Effects: Additionally, pirfenidone exhibits antioxidant and anti-inflammatory properties, which may contribute to its therapeutic effects in IPF by reducing oxidative stress and inflammation in the lungs.